Patents by Inventor Cornelis Van Berkel

Cornelis Van Berkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLYCOCONJUGATES
    Publication number: 20240042053
    Abstract: Disclosed herein are glycoconjugates having a cell-binding agent, such as an antibody, conjugating to a payload, such as a drug. The drug is conjugated to the cell-binding agent through an oligosaccharide linker. The glycoconjugates conjugated through the oligosaccharide linkers disclosed herein exhibit improved properties over prior glycoconjugates.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 8, 2024
    Inventors: Gerardus Josephus BOONS, Xiuru LI, Patricius Hendrikus Cornelis VAN BERKEL
  • GLYCOCONJUGATES
    Publication number: 20230372528
    Abstract: This disclosure relates to glycoconjugates comprising glycosylated cell-binding agents conjugated to pyrrolobenzodiazepine (PBD) payloads. Glycoconjugates of particular interest include conjugates where the cell-binding agent is an antibody and the payload comprises a cytotoxic pyrrolobenzodiazepine (PBD) moiety, with the PBD moiety conjugated to the antibody via an oligosaccharide linker. The disclosure also relates to methods for preparing the glycoconjugates, along with methods for their use.
    Type: Application
    Filed: October 14, 2021
    Publication date: November 23, 2023
    Inventors: Gerardus Josephus BOONS, Xiuru LI, Patricius Hendrikus Cornelis VAN BERKEL
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11813335
    Abstract: A conjugate of formula (I): Ab-(DL)p??(I) wherein: Ab is an antibody that binds to AXL; DL is
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: November 14, 2023
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS SA
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11779650
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: October 10, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11771775
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: October 3, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • ANTI-IL-13RALPHA2 CONJUGATES
    Publication number: 20230285580
    Abstract: This disclosure relates to antibody conjugates comprising antibodies that bind specifically to the Interleukin-13 receptor subunit alpha-2 (IL-13R?2) protein, conjugated to cytotoxic warheads, and associated uses.
    Type: Application
    Filed: November 16, 2022
    Publication date: September 14, 2023
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Ian KIRBY
  • Site-specific antibody-drug conjugates
    Patent number: 11702473
    Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: July 18, 2023
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
    Patent number: 11690918
    Abstract: The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: July 4, 2023
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • ANTI-PSMA CONJUGATES
    Publication number: 20230201366
    Abstract: This disclosure relates to antibody conjugates comprising antibodies that bind specifically to prostate-specific membrane antigen (PSMA), conjugated to cytotoxic warheads, and associated uses.
    Type: Application
    Filed: November 16, 2022
    Publication date: June 29, 2023
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Ian KIRBY
  • COMBINATION THERAPY
    Publication number: 20230149556
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC),a secondary agent, and optionally an anti-CD20 agent.
    Type: Application
    Filed: August 11, 2022
    Publication date: May 18, 2023
    Inventors: Jay Marshall FEINGOLD, Patricius Hendrikus Cornelis VAN BERKEL, Jens WUERTHNER, John HARTLEY, Francesca ZAMMARCHI
  • COMBINATION THERAPY
    Publication number: 20230132256
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD25 ADC and Gemcitabine.
    Type: Application
    Filed: July 8, 2019
    Publication date: April 27, 2023
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Francesca ZAMMARCHI, John HARTLEY
  • COMBINATION THERAPY
    Publication number: 20230099010
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with Antibody Drug Conjugates (ADCs) ADCs which bind to CD25 (CD25-ADCs) and radiotherapy.
    Type: Application
    Filed: November 6, 2020
    Publication date: March 30, 2023
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Francesca ZAMMARCHI, Jens WUERTHNER
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11612665
    Abstract: A conjugate of formula (I): Ab-(DL)p wherein: Ab is an antibody, or an active fragment of an antibody; DL is (II).
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: March 28, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • Combination therapy with an anti-CD25 antibody-drug conjugate
    Patent number: 11596696
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: March 7, 2023
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20230053603
    Abstract: The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.
    Type: Application
    Filed: June 3, 2022
    Publication date: February 23, 2023
    Inventor: Patricius Hendrikus Cornelis VAN BERKEL
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11484606
    Abstract: The present disclosure relates to pyrrolobenzodiazepines (PBDs) having a labile C2 or N10 protecting group in the form of a linker to an antibody.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: November 1, 2022
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11384098
    Abstract: The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: July 12, 2022
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • MOLECULAR ADJUVANT
    Publication number: 20220111065
    Abstract: The present disclosure relates to therapies for the treatment of a disorders characterized by a disorder-associated antigen (DAA); vaccination methods are disclosed. In particular, the disclosure describes anti-CD25 ADC molecular adjuvants for use in inducing or enhancing a subject's immune response against a DAA, allowing for treatment of the disorder characterized by the DAA. Also disclosed are dosage regiments for the treatment of solid tumours with an AThe present disclosure relates to the treatment of pathological conditions, such as cancer, with anti-CD25 ADCs.
    Type: Application
    Filed: May 22, 2019
    Publication date: April 14, 2022
    Inventors: Patrick Hendrikus Cornelis VAN BERKEL, Jay Marshall FEINGOLD, Jens WUERTHNER, James ADAMS
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF
    Publication number: 20220096654
    Abstract: The present disclosure relates to novel pyrrolobenzodiazepine antibody-drug conjugates (PBD-ADCs) and therapeutic uses thereof.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 31, 2022
    Inventors: Patricius Hendrikus Cornelis van Berkel, Persis Amrolia, Kerry Chester, Jenny Yeung
  • HUMANIZED ANTI-AXL ANTIBODIES
    Publication number: 20220073625
    Abstract: The present disclosure relates to humanized anti-Axl antibodies.
    Type: Application
    Filed: July 12, 2021
    Publication date: March 10, 2022
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, DAVID G. WILLIAMS